A328130 Stock Overview
Develops and provides AI based software solutions for cancer screening/diagnosis and treatment.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Lunit Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩41,750.00 |
| 52 Week High | ₩122,500.00 |
| 52 Week Low | ₩31,000.00 |
| Beta | 1.94 |
| 11 Month Change | 11.78% |
| 3 Month Change | -17.82% |
| 1 Year Change | -63.85% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 108.75% |
Recent News & Updates
Shareholder Returns
| A328130 | KR Healthcare Services | KR Market | |
|---|---|---|---|
| 7D | 9.9% | -2.2% | -5.7% |
| 1Y | -63.9% | -59.6% | -3.9% |
Return vs Industry: A328130 underperformed the KR Healthcare Services industry which returned -59.6% over the past year.
Return vs Market: A328130 underperformed the KR Market which returned -3.9% over the past year.
Price Volatility
| A328130 volatility | |
|---|---|
| A328130 Average Weekly Movement | 10.5% |
| Healthcare Services Industry Average Movement | 8.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 11.9% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A328130's share price has been volatile over the past 3 months.
Volatility Over Time: A328130's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 290 | Beomseok Brandon Suh | www.lunit.io |
Lunit Inc. develops and provides AI based software solutions for cancer screening/diagnosis and treatment. It offers AI solution for chest X-ray and mammography, as well as AI-powered biomarker for immune phenotyping and PD-L1 quantification for immunotherapy. The company was incorporated in 2013 and is based in Seoul, South Korea.
Lunit Inc. Fundamentals Summary
| A328130 fundamental statistics | |
|---|---|
| Market cap | ₩1.21t |
| Earnings (TTM) | -₩22.06b |
| Revenue (TTM) | ₩26.03b |
46.3x
P/S Ratio-54.7x
P/E RatioIs A328130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A328130 income statement (TTM) | |
|---|---|
| Revenue | ₩26.03b |
| Cost of Revenue | ₩0 |
| Gross Profit | ₩26.03b |
| Other Expenses | ₩48.09b |
| Earnings | -₩22.06b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -763.91 |
| Gross Margin | 100.00% |
| Net Profit Margin | -84.72% |
| Debt/Equity Ratio | 19.1% |
How did A328130 perform over the long term?
See historical performance and comparison